Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7MDP

KRas G12C in complex with G-2897

Summary for 7MDP
Entry DOI10.2210/pdb7mdp/pdb
DescriptorIsoform 2B of GTPase KRas, 1,2-ETHANEDIOL, DIMETHYL SULFOXIDE, ... (12 entities in total)
Functional Keywordskras, gtpase, hydrolase, hydrolase-immune system complex, hydrolase/immune system
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains3
Total formula weight68897.33
Authors
Oh, A.,Frank, Y.,Wang, W. (deposition date: 2021-04-05, release date: 2022-03-16, Last modification date: 2024-10-30)
Primary citationDavies, C.W.,Oh, A.J.,Mroue, R.,Steffek, M.,Bruning, J.M.,Xiao, Y.,Feng, S.,Jayakar, S.,Chan, E.,Arumugam, V.,Uribe, S.C.,Drummond, J.,Frommlet, A.,Lu, C.,Franke, Y.,Merchant, M.,Koeppen, H.,Quinn, J.G.,Malhotra, S.,Do, S.,Gazzard, L.,Purkey, H.E.,Rudolph, J.,Mulvihill, M.M.,Koerber, J.T.,Wang, W.,Evangelista, M.
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors.
Nat.Biotechnol., 40:769-778, 2022
Cited by
PubMed Abstract: Small molecules that stabilize inactive protein conformations are an underutilized strategy for drugging dynamic or otherwise intractable proteins. To facilitate the discovery and characterization of such inhibitors, we created a screening platform to identify conformation-locking antibodies for molecular probes (CLAMPs) that distinguish and induce rare protein conformational states. Applying the approach to KRAS, we discovered CLAMPs that recognize the open conformation of KRAS stabilized by covalent inhibitors. One CLAMP enables the visualization of KRAS covalent modification in vivo and can be used to investigate response heterogeneity to KRAS inhibitors in patient tumors. A second CLAMP enhances the affinity of weak ligands binding to the KRAS switch II region (SWII) by stabilizing a specific conformation of KRAS, thereby enabling the discovery of such ligands that could serve as leads for the development of drugs in a high-throughput screen. We show that combining the complementary properties of antibodies and small molecules facilitates the study and drugging of dynamic proteins.
PubMed: 34992247
DOI: 10.1038/s41587-021-01126-9
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.96 Å)
Structure validation

246333

数据于2025-12-17公开中

PDB statisticsPDBj update infoContact PDBjnumon